Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
about
Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domainSurfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI InhibitorsTargeting kinase signaling pathways with constrained peptide scaffolds.A conformationally constrained peptidomimetic binds to the extracellular region of HER2 proteinStructure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.Combined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors.Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin.Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.Trastuzumab-Peptide interactions: mechanism and application in structure-based ligand designStructure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.Structure-based and ligand-based drug design for HER 2 receptor.A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.Development and Analytical Validation of a BT-474 Anti-Proliferation Assay Targeting HER2
P2860
Q24293331-C9E8404B-0D51-48C3-877D-7B0ECC5A559AQ26823990-1AB93BE6-C821-48A4-812B-E892BB57574DQ30398451-ED5357A8-AF97-496F-82F9-350959FAAAEFQ34422576-8ECC07FE-4F4C-4BAC-90BC-59A4F7E5328BQ35185574-462122D2-3FD8-415A-8979-901D90DEEB0CQ35771539-0EF75F4A-5CA1-4833-94BA-383A5AD0623DQ35937896-95343DD6-090A-4511-992D-09D43A294B8FQ36171074-A20D2F71-17EE-4490-AB50-37157E67F315Q36425044-29602298-1B33-4C47-A51D-61AB64392C45Q36610755-936AC452-F69D-4268-81B3-7A76FEA47F43Q37139227-527ECD31-6925-4BAF-B4D0-B05E68566532Q37721805-4CD33A80-4CDE-40B0-A50A-78A8069BD5BFQ39272792-F481D82A-05B0-49C2-A39F-E94A6D296BD6Q43061745-D4ACDAB9-611B-46A1-AE18-AE9896FB0330Q44114723-216352DE-E998-4339-94C5-DF22C3052B56Q58126050-4CF23649-DC5C-4AEA-A223-67101247F21E
P2860
Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Design, synthesis, and docking ...... inst breast cancer cell lines.
@ast
Design, synthesis, and docking ...... inst breast cancer cell lines.
@en
type
label
Design, synthesis, and docking ...... inst breast cancer cell lines.
@ast
Design, synthesis, and docking ...... inst breast cancer cell lines.
@en
prefLabel
Design, synthesis, and docking ...... inst breast cancer cell lines.
@ast
Design, synthesis, and docking ...... inst breast cancer cell lines.
@en
P2093
P2860
P1476
Design, synthesis, and docking ...... inst breast cancer cell lines.
@en
P2093
Go Mei Lin
Liu Jianchao
Seetharama Satyanarayanajois
Stephanie Villalba
P2860
P304
P356
10.1111/J.1747-0285.2009.00855.X
P577
2009-09-01T00:00:00Z